| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Shire LLC v. Amerigan Pharms. Ltd., 14-6095 (D.N.J.) | Oct. 1, 2014 | Hon. Renee Marie Bumb | Adderall XR® (dextroamphetamine sulfate / dextroamphetamine saccharate / amphetamine aspartate monohydrate / amphetamine sulfate tablets) |
RE42,096 RE41,148 |
| Supernus Pharms., Inc. v. Actavis, Inc., 14-6102 (D.N.J.) | Oct. 1, 2014 | Hon. Susan D. Wigenton | Trokendi XR® (topiramate extended-release capsules) | 8,298,576 8,298,580 8,663,683 |
| Kowa Co., Ltd. v. Apotex, Inc., 14-7934 (S.D.N.Y.) | Oct. 1, 2014 | Hon. Paul A. Crotty | Livalo® (pitavastatin calcium tablets) | 8,557,993 |
| Sandoz Inc. v. EKR Therapeutics, LLC, IPR2015-00005 (PTAB) | Oct. 1, 2014 | N/A | Cardene® (nicardipine hydrochloride) | 8,455,524 |
| Sandoz Inc. v. EKR Therapeutics, LLC, IPR2015-00006 (PTAB) | Oct. 1, 2014 | N/A | Cardene® (nicardipine hydrochloride) | 7,612,102 |
| Sandoz Inc. v. EKR Therapeutics, LLC, IPR2015-00007 (PTAB) | Oct. 1, 2014 | N/A | Cardene® (nicardipine hydrochloride) | 7,659,290 |
| Sandoz Inc. v. EKR Therapeutics, LLC, IPR2015-00008 (PTAB) | Oct. 1, 2014 | N/A | Cardene® (nicardipine hydrochloride) | 7,659,291 |
| Kowa Co., Ltd. v. Apotex, Inc., 14-1264 (D. Del.) | Oct. 2, 2014 | Hon. Sue L. Robinson | Livalo® (pitavastatin calcium tablets) | 8,557,993 |
| Forest Labs., LLC v. Hikma Pharms., LLC, 14-1266 (D. Del.) | Oct. 2, 2014 | Hon. Sue L. Robinson | Saphris® (asenapine maleate tablets) | 8,022,228 7,741,358 |
| Jazz Pharms., Inc. v. Par Pharm., Inc., 14-6150 (D.N.J.) | Oct. 2, 2014 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 8,772,306 |
| Jazz Pharms., Inc. v. Ranbaxy Labs., Ltd., 14-6151 (D.N.J.) | Oct. 2, 2014 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 8,772,306 |
| Otsuka Pharm. Co., Ltd. v. Intas Pharms. Ltd., 14-6158 (D.N.J.) | Oct. 2, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,759,350 |
| Forest Labs, LLC v. Amerigan Pharms., Inc., 14-1271 (D. Del.) | Oct. 3, 2014 | Hon. Leonard P. Stark | Namenda XR® (memantine hydrochloride extended-release capsules) |
8,039,009 8,168,209 8,173,708 8,283,379 8,329,752 8,362,085 8,598,233 |
| Teva Pharms. USA, Inc. v. Mylan Pharms. Inc., 14-1278 (D. Del.) | Oct. 6, 2014 | Hon. Gregory M. Sleet | Copaxone® (glatiramer acetate for injection) | 8,232,250 8,399,413 |
| Otsuka Pharm. Co., Ltd. v. Sun Pharm. Industries Ltd., 14-6397 (D.N.J.) | Oct. 6, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,759,350 |
| Teva Pharms. USA, Inc. v. Mylan Pharms. Inc., 14-0167 (N.D.W.V.) | Oct. 7, 2014 | Hon. Irene M. Keeley | Copaxone® (glatiramer acetate for injection) | 8,232,250 8,399,413 |
| Novartis Pharms. Corp. v. Dr. Reddy’s Labs., Ltd., 14-1283 (D. Del.) | Oct. 8, 2014 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate capsules) | 6,894,051 RE43,932 |
| Eli Lilly and Co. v. Nang Kuang Pharm. Co., Ltd., 14-1647 (S.D. Ind.) | Oct. 8, 2014 | Hon. Jane Magnus-Stinson | Alimta® (pemetrexed disodium for intravenous infusion) | 5,344,932 7,772,209 |
| AbbVie Inc. v. Mylan Pharms. Inc., 14-1288 (D. Del.) | Oct. 9, 2014 | Hon. Richard G. Andrews | Norvir® (ritonavir tablets) | 7,148,359 7,364,752 |
| Novartis Pharms. Corp. v. Dr. Reddy’s Labs., Ltd., 14-6280 (D.N.J.) | Oct. 9, 2014 | Hon. Claire C. Cecchi | Gleevec® (imatinib mesylate capsules) | 6,894,051 RE43,932 |
| Braintree Labs., Inc. v. Taro Pharms. USA, Inc., 14-8147 (S.D.N.Y.) | Oct. 9, 2014 | Hon. Alison J. Nathan | Suprep® (sodium sulfate, potassium sulfate, magnesium sulfate oral solution) | 6,946,149 |
| Novartis Pharms. Corp. v. Par Pharm., Inc., 14-1289 (D. Del.) | Oct. 10, 2014 | Hon. Richard G. Andrews | Zortress® (everolimus tablets) | 5,665,772 6,004,973 6,455,518 |
| Otsuka Pharm. Co., Ltd. v. Amneal Pharms., LLC, 14-6340 (D.N.J.) | Oct. 10, 2014 | Hon. Mary L. Cooper | Abilify® (aripiprazole oral solution) | 8,759,350 |
| Otsuka Pharm. Co., Ltd. v. Teva Pharms. USA, Inc., 14-6398 (D.N.J.) | Oct. 10, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,580,796 8,642,760 |
| Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 14-6341 (D.N.J.) | Oct. 13, 2014 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride IV solutions) | 8,729,094 |
| Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 14-1309 (D. Del.) | Oct. 15, 2014 | Hon. Gregory M. Sleet | Quillivant XR® (methylphenidate hydrochloride extended-release oral suspension) | 8,465,765 8,563,033 8,778,390 |
| Noven Therapeutics, LLC v. Actavis Labs. FL, Inc., 14-6414 (D.N.J.) | Oct. 16, 2014 | Hon. Faith S. Hochberg | Brisdelle® (paroxetine mesylate capsule) | 5,874,447 7,598,271 8,658,663 |
| Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 14-6425 (D.N.J.) | Oct. 16, 2014 | Hon. Stanley R. Chesler | Quillivant XR® (methylphenidate hydrochloride extended-release oral suspension) | 8,465,765 8,563,033 8,778,390 |
| Cephalon, Inc. v. Wockhardt Bio Ltd., 14-1332 (D. Del.) | Oct. 21, 2014 | Hon. Gregory M. Sleet | Treanda® (bendamustine hydrochloride for infusion) | 8,445,524 8,436,190 8,609,863 8,791,270 |
| AstraZeneca Pharms. LP v. Pharmadax USA, Inc., 14-6557 (D.N.J.) | Oct. 22, 2014 | Hon. Noel L. Hillman | Seroquel® XR (quetiapine fumarate extended-release tablets) | 5,948,437 |
| AstraZeneca Pharms. LP v. Pharmadax USA, Inc., 14-1710 (C.D. Cal.) | Oct. 23, 2014 | Hon. James V. Selna | Seroquel® XR (quetiapine fumarate extended-release tablets) | 5,948,437 |
| Agila Specialties Inc. v. Cubist Pharms., Inc., IPR2015-00131 (PTAB) | Oct. 23, 2014 | N/A | Cubicin® (daptomycin for injection) | 6,468,967 |
| Agila Specialties Inc. v. Cubist Pharms., Inc., IPR2015-00132 (PTAB) | Oct. 23, 2014 | N/A | Cubicin® (daptomycin for injection) | 6,852,689 |
| Agila Specialties Inc. v. Cubist Pharms., Inc., IPR2015-00140 (PTAB) | Oct. 23, 2014 | N/A | Cubicin® (daptomycin for injection) | 8,129,342 |
| Agila Specialties Inc. v. Cubist Pharms., Inc., IPR2015-00141 (PTAB) | Oct. 23, 2014 | N/A | Cubicin® (daptomycin for injection) | 8,058,238 |
| Agila Specialties Inc. v. Cubist Pharms., Inc., IPR2015-00142 (PTAB) | Oct. 23, 2014 | N/A | Cubicin® (daptomycin for injection) | 8,058,238 |
| Agila Specialties Inc. v. Cubist Pharms., Inc., IPR2015-00143 (PTAB) | Oct. 23, 2014 | N/A | Cubicin® (daptomycin for injection) | 8,058,238 |
| Agila Specialties Inc. v. Cubist Pharms., Inc., IPR2015-00144 (PTAB) | Oct. 24, 2014 | N/A | Cubicin® (daptomycin for injection) | 8,058,238 |
| Otsuka Pharm. Co., Ltd. v. Apotex Corp., 14-6707 (D.N.J.) | Oct. 27, 2014 | Hon. Mary L. Cooper | Abilify® (aripiprazole oral solution) | 7,053,092 8,642,600 8,759,350 |
| AstraZeneca AB v. Actavis Labs. FL, Inc., 14-1356 (D. Del.) | Oct. 31, 2014 | Hon. Gregory M. Sleet | Kombiglyze® XR (saxagliptin hydrochloride / metformin hydrochloride tablets) | RE44,186 8,628,799 |
| Otsuka Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 14-6890 (D.N.J.) | Oct. 31, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,759,350 |
| Daravita Ltd. v. Alvogen Pine Brook, Inc., 14-1364 (D. Del.) | Nov. 3, 2014 | Hon. Gregory M. Sleet | Zohydro ER® (hydrocodone bitartrate extended-release capsules) | 6,228,398 6,902,742 |
| Senju Pharm. Co., Ltd. v. Innopharma Licensing, Inc., 14-6893 (D.N.J.) | Nov. 3, 2014 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) | 8,129,431 8,669,290 8,754,131 8,871,813 |
| Otsuka Pharm. Co., Ltd. v. Lupin Ltd., 14-7105 (D.N.J.) | Nov. 3, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,017,615 8,580,796 8,642,760 8,759,350 |
| Fresenius-Kabi USA LLC v. Cubist Pharms., Inc., IPR2015-00223 (PTAB) | Nov. 3, 2014 | N/A | Cubicin® (daptomycin for injection) | 6,852,689 |
| Fresenius-Kabi USA LLC v. Cubist Pharms., Inc., IPR2015-00227 (PTAB) | Nov. 3, 2014 | N/A | Cubicin® (daptomycin for injection) | 6,468,967 |
| Teijin Ltd. v. Unimark Remedies, Ltd., 14-1370 (D. Del.) | Nov. 4, 2014 | Hon. Sue L. Robinson | Uloric® (febuxostat tablets) | 7,361,676 |
| Endo Pharms. Inc. v. Actavis Inc., 14-1381 (D. Del.) | Nov. 7, 2014 | Hon. Richard G. Andrews | Opana ER® (oxymorphone hydrochloride extended-release tablets) | 8,808,737 8,871,779 |
| Endo Pharms. Inc. v. Amneal Pharms., LLC, 14-1382 (D. Del.) | Nov. 7, 2014 | Hon. Richard G. Andrews | Opana ER® (oxymorphone hydrochloride extended-release tablets) | 8,808,737 8,871,779 |
| Endo Pharms. Inc. v. Impax Labs., Inc., 14-1383 (D. Del.) | Nov. 7, 2014 | Hon. Richard G. Andrews | Opana ER® (oxymorphone hydrochloride extended-release tablets) | 8,808,737 8,871,779 |
| Endo Pharms. Inc. v. Impax Labs., Inc., 14-1384 (D. Del.) | Nov. 7, 2014 | Hon. Richard G. Andrews | Opana ER® (oxymorphone hydrochloride extended-release tablets) | 8,808,737 8,871,779 |
| Endo Pharms. Inc. v. Par Pharm. Companies, Inc., 14-1385 (D. Del.) | Nov. 7, 2014 | Hon. Richard G. Andrews | Opana ER® (oxymorphone hydrochloride extended-release tablets) | 8,808,737 8,871,779 |
| Endo Pharms. Inc. v. Ranbaxy Labs. Ltd., 14-1386 (D. Del.) | Nov. 7, 2014 | Hon. Richard G. Andrews | Opana ER® (oxymorphone hydrochloride extended-release tablets) | 8,808,737 8,871,779 |
| Endo Pharms. Inc. v. Roxane Labs., Inc., 14-1387 (D. Del.) | Nov. 7, 2014 | Hon. Richard G. Andrews | Opana ER® (oxymorphone hydrochloride extended-release tablets) | 8,808,737 8,871,779 |
| Endo Pharms. Inc. v. Sandoz, Inc., 14-1388 (D. Del.) | Nov. 7, 2014 | Hon. Richard G. Andrews | Opana ER® (oxymorphone hydrochloride extended-release tablets) | 8,808,737 8,871,779 |
| Endo Pharms. Inc. v. Teva Pharms. USA, Inc., 14-1389 (D. Del.) | Nov. 7, 2014 | Hon. Richard G. Andrews | Opana ER® (oxymorphone hydrochloride extended-release tablets) | 8,808,737 8,871,779 |
| AstraZeneca Pharms. LP v. Pharmadax USA, Inc., 14-7007 (D.N.J.) | Nov. 7, 2014 | Hon. Noel L. Hillman | Seroquel® XR (quetiapine fumarate extended-release tablets) | 5,948,437 |
| Shire Development Natco Pharma Ltd., 14-7053 (D.N.J.) | Nov. 10, 2014 | Hon. Stanley R. Chesler | Fosrenol® (lanthanum carbonate chewable tablets) | 5,968,976 7,381,428 7,465,465 |
| Otsuka Pharm. Co., Ltd. v. Actavis Elizabeth LLC, 14-7106 (D.N.J.) | Nov. 10, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,580,796 8,642,760 8,759,350 |
| Pfizer Inc. v. Tiger Pharms., LLC, 14-1501 (E.D. Va.) | Nov. 10, 2014 | Hon. Anthony J. Trenga | Tikosyn® (dofetilide capsules) | 6,124,363 |
| Pfizer Inc. v. Tiger Pharms., LLC, 14-8958 (S.D.N.Y.) | Nov. 10, 2014 | Hon. Gregory H. Woods | Tikosyn® (dofetilide capsules) | 6,124,363 |
| Baxter Healthcare Corp. v. Agila Specialties Private Ltd., 14-7094 (D.N.J.) | Nov. 12, 2014 | Hon. Faith S. Hochberg | Brevibloc® (esmolol hydrochloride in sodium chloride solution) | 6,310,094 6,528,540 |
| Sucampo AG v. Dr. Reddy’s Labs., Inc., 14-7114 (D.N.J.) | Nov. 12, 2014 | Hon. Michael A. Shipp | Amitiza® (lubiprostone capsules) | 6,414,016 8,071,613 7,795,312 8,097,653 8,389,542 8,026,393 8,338,639 |
| Mylan Pharms. Inc. v. Novartis AG, IPR2015-00265 (PTAB) | Nov. 13, 2014 | N/A | Exelon® Patch (rivastigmine transdermal system or extended-release film) | 6,316,023 |
| Mylan Pharms. Inc. v. Novartis AG, IPR2015-00268 (PTAB) | Nov. 13, 2014 | N/A | Exelon® Patch (rivastigmine transdermal system or extended-release film) | 6,335,031 |
| Baxter Healthcare Corp. v. Agila Specialties Private Ltd., 14-0190 (N.D.W.V.) | Nov. 13, 2014 | Hon. Irene M. Keeley | Brevibloc® (esmolol hydrochloride in sodium chloride solution) | 6,310,094 6,528,540 |
| Purdue Pharma L.P. v. Watson Labs., Inc., 14-1410 (D. Del.) | Nov. 14, 2014 | Hon. Sue L. Robinson | Butrans® (buprenorphine transdermal system) | RE41,408 RE41,489 RE41,571 |
| BioMarin Pharm. Inc. v. Dr. Reddy’s Labs., Inc., 14-7203 (D.N.J.) | Nov. 17, 2014 | Hon. Michael A. Shipp | Kuvan® (sapropterin dihydrochloride tablets) | 7,566,462 7,566,714 7,612,073 8,003,126 8,067,416 RE43,797 8,318,745 |
| Teva Pharms. USA, Inc. v. Synthon Pharms. Inc., 14-1419 (D. Del.) | Nov. 18, 2014 | Hon. Gregory M. Sleet | Copaxone® (glatiramer acetate for injection) | 8,232,250 8,399,413 |
| Teva Pharms. USA, Inc. v. Synthon Pharms. Inc., 14-0975 (D. Del.) | Nov. 19, 2014 | Hon. Catherine C. Eagles | Copaxone® (glatiramer acetate for injection) | 8,232,250 8,399,413 |
| Par Pharm., Inc. v. GlaxoSmithKline LLC, 14-6627 (E.D. Pa.) | Nov. 19, 2014 | Hon. Nitza I. Quinones Alejandro | Lamictal ODT® (lamotrigine tablets) | 7,919,115 |
| Endo Pharms. Solutions Inc. v. Paddock Labs., LLC, 14-1422 (D. Del.) | Nov. 20, 2014 | Hon. Sue L. Robinson | Aveed® (testosterone undecanoate for injection) | 7,718,640 8,338,395 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., 14-7252 (D.N.J.) | Nov. 20, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,017,615 8,580,796 8,642,760 |
| AstraZeneca AB v. Actavis Labs. FL, Inc., 14-7263 (D.N.J.) | Nov. 20, 2014 | Hon. Mary L. Cooper | Nexium 24HR® (esomeprazole magnesium delayed-release capsules) | 6,369,085 7,411,070 |
| Supernus Pharms., Inc. v. Zydus Pharms. (USA) Inc., 14-7272 (D.N.J.) | Nov. 21, 2014 | Hon. Susan D. Wigenton | Trokendi XR® (topiramate extended-release capsules) | 8,298,576 8,298,580 8,663,683 |
| Sanofi v. Sandoz Inc., 14-1434 (D. Del.) | Nov. 24, 2014 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 8,318,800 8,410,167 8,602,215 |
| Fresenius Kabi USA, LLC v. Agila Specialties Private Ltd., 14-1438 (D. Del.) | Nov. 26, 2014 | Hon. Richard G. Andrews | Diprivan® (propofol injectable) | 8,476,010 |
| Fresenius Kabi USA, LLC v. Agila Specialties Private Ltd., 14-0205 (N.D.W.V.) | Nov. 26, 2014 | Hon. Irene M. Keeley | Diprivan® (propofol injectable) | 8,476,010 |
| Noven Therapeutics, LLC v. Prinston Pharm. Inc., 14-7400 (D.N.J.) | Nov. 26, 2014 | Hon. Faith S. Hochberg | Brisdelle® (paroxetine mesylate capsule) | 5,874,447 7,598,271 8,658,663 |
| Otsuka Pharm. Co., Ltd. v. Alembic Pharms. Ltd., 14-7405 (D.N.J.) | Nov. 26, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,759,350 |
| Bausch & Lomb Inc. v. Micro Labs USA, Inc., 14-7406 (D.N.J.) | Nov. 26, 2014 | Hon. Noel L. Hillman | Bepreve® (bepotastine besilate ophthalmic solution) | 8,784,789 |
| Reckitt Benckiser Pharms. Inc. v. Teva Pharms. USA, Inc., 14-1451 (D. Del.) | Dec. 2, 2014 | Hon. Richard G. Andrews | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) | 8,475,832 8,017,150 8,603,514 |
| Meda Pharms. Inc. v. Apotex Inc., 14-1453 (D. Del.) | Dec. 2, 2014 | Hon. Leonard P. Stark | Dymista® (azelastine hydrochloride / fluticasone propionate nasal spray) | 8,163,723 8,168,620 |
| Novartis Pharms. Corp. v. Amneal Pharms., LLC, 14-7557 (D.N.J.) | Dec. 3, 2014 | Hon. Susan D. Wigenton | Zometa® (zoledronic acid for injection) | 8,324,189 |
| Novartis Pharms. Corp. v. Par Sterile Products, LLC, 14-7558 (D.N.J.) | Dec. 3, 2014 | Hon. Susan D. Wigenton | Zometa® / Reclast® (zoledronic acid for injection) | 7,932,241 8,052,987 8,324,189 |
| Allergan, Inc. v. Wilshire Pharms., Inc., 14-1461 (D. Del.) | Dec. 4, 2014 | Hon. Leonard P. Stark | Lastacaft® (alcaftadine ophthalmic solution) | 8,664,215 |
| Eli Lilly and Co. v. Sandoz Inc., 14-2008 (S.D. Ind.) | Dec. 5, 2014 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
| Fresenius Medical Care Holdings, Inc. v. Lotus Pharms. Co., Ltd., 14-14345 (D. Mass.) | Dec. 5, 2014 | Hon. Richard G. Stearns | PhosLo® GelCaps (calcium acetate) | 6,576,665 |
| Fresenius Medical Care Holdings, Inc. v. Lotus Pharms. Co., Ltd., 14-7612 (D.N.J.) | Dec. 5, 2014 | Hon. Stanley R. Chesler | PhosLo® GelCaps (calcium acetate) | 6,576,665 |
| Teva Women’s Health, Inc. v. Famy Care Ltd., 14-9637 (S.D.N.Y.) | Dec. 5, 2014 | Hon. Shira A. Scheindlin | Quartette® (levonorgestrel / ethinyl estradiol and ethinyl estradiol tablets) | 8,415,332 8,450,299 |
| AstraZeneca AB v. Aurobindo Pharma Ltd., 14-1469 (D. Del.) | Dec. 9, 2014 | Hon. Gregory M. Sleet | Onglyza® (saxagliptin hydrochloride tablets) | RE44,186 |
| Duke University v. Apotex, Inc., 14-1028 (M.D.N.C) | Dec. 9, 2014 | Hon. Catherine C. Eagles | Latisse® (bimatoprost topical solution) | 8,906,962 |
| Eli Lilly and Co. v. Amneal Pharms. LLC, 14-2025 (S.D. Ind.) | Dec. 10, 2014 | Hon. Sarah Evans Barker | Axiron® (testosterone metered transdermal solution) | 8,435,449 8,419,307 8,177,409 8,807,861 |
| Duke University v. Sandoz, Inc., 14-1034 (M.D.N.C.) | Dec. 10, 2014 | Hon. Catherine C. Eagles | Latisse® (bimatoprost topical solution) | 8,906,962 |
| Lupin Ltd. v. ViiV Healthcare Co., IPR2015-00405 (PTAB) | Dec. 10, 2014 | N/A | Lexiva® (fosamprenavir calcium) | 6,436,989 |
| Eli Lilly and Co. v. Amneal Pharms. LLC, 14-1474 (D. Del.) | Dec. 11, 2014 | Hon. Sue L. Robinson | Axiron® (testosterone metered transdermal solution) | 8,435,449 8,419,307 8,177,409 8,807,861 |
| Jazz Pharms., Inc. v. Watson Labs., Inc., 14-7757 (D. Del.) | Dec. 11, 2014 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 6,472,431 6,780,889 7,262,219 7,851,506 8,263,650 8,324,275 8,461,203 7,668,730 7,765,106 7,765,107 7,895,059 8,457,988 8,589,182 8,731,963 8,772,306 |
| Apotex Inc. v. Merck and Co., Inc., IPR2015-00419 (PTAB) | Dec. 11, 2014 | N/A | Emend® (fosaprepitant dimeglumine) | 5,691,336 |
| AstraZeneca Pharms. LP v. Teva Pharms. USA, Inc., 14-1478 (D. Del.) | Dec. 12, 2014 | Hon. Gregory M. Sleet | Byetta® (exenatide injection) | 6,858,576 6,872,700 6,956,026 7,297,761 6,902,744 7,521,423 7,741,269 |
| Shire Development LLC v. Invagen Pharms., Inc., 14-7263 (E.D.N.Y.) | Dec. 12, 2014 | Hon. Brian M. Cogan | Fosrenol® (lanthanum carbonate chewable tablets) | 5,968,976 7,381,428 7,465,465 |
| Boehringer Ingelheim Pharma Gmbh v. Teva Pharms. USA, Inc., 14-7811 (D.N.J.) | Dec. 15, 2014 | Hon. Mary L. Cooper | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
| Novartis AG v. Actavis, Inc., 14-1487 (D. Del.) | Dec. 16, 2014 | Hon. Leonard P. Stark | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| Novartis AG v. Actavis, Inc., 14-7849 (D.N.J.) | Dec. 17, 2014 | Hon. Madeline C. Arleo | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| AstraZeneca AB v. Actavis Labs. FL, Inc., 14-7870 (D.N.J.) | Dec. 17, 2014 | Hon. Joel A. Pisano | Nexium® (esomeprazole magnesium delayed-release capsules) | 5,714,504 6,369,085 7,411,070 8,466,175 |
| Novartis Pharms. Corp. v. Par Pharm., Inc., 14-1494 (D. Del.) | Dec. 18, 2014 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) | 5,665,772 7,297,703 7,741,338 |
| Ranbaxy Labs. Ltd v. Adamas Pharms., Inc., IPR2015-00410 (PTAB) | Dec. 18, 2014 | N/A | Namenda XR® (memantine hydrochloride extended-release capsules) | 8,362,085 |
| Fresenius Kabi USA, LLC v. Claris Lifesciences Ltd., 14-1498 (D. Del.) | Dec. 19, 2014 | Hon. Richard G. Andrews | Diprivan® (propofol injectable) | 8,476,010 |
| Cadence Pharms., Inc. v. Agila Specialties Private Ltd., Inc., 14-1499 (D. Del.) | Dec. 19, 2014 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 6,028,222 6,992,218 |
| Fresenius Kabi USA, LLC v. Claris Lifesciences Ltd., 14-7953 (D.N.J.) | Dec. 19, 2014 | Hon. Noel L. Hillman | Diprivan® (propofol injectable) | 8,476,010 |
| Forest Labs., LLC v. Breckenridge Pharm., Inc., 14-1504 (D. Del.) | Dec. 22, 2014 | Hon. Sue L. Robinson | Saphris® (asenapine maleate tablets) | 5,763,476 8,022,228 7,741,358 |
| Otsuka Pharm. Co., Ltd. v. Sciegen Pharms. Inc., 14-8077 (D.N.J.) | Dec. 22, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,017,615 8,580,796 8,642,760 |
| Novartis Pharms. Corp. v. Roxane Labs., Inc., 14-1508 (D. Del.) | Dec. 23, 2014 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) | 5,665,772 7,297,703 7,741,338 |
| Eisai Co., Ltd. v. Roxane Labs., Inc., 14-1511 (D. Del.) | Dec. 23, 2014 | Hon. Leonard P. Stark | Banzel® (rufinamide oral suspension) | 6,740,669 7,750,028 |
| Iceutica Pty Ltd. v. Lupin Ltd., 14-1515 (D. Del.) | Dec. 23, 2014 | Hon. Sue L. Robinson | Zorvolex® (diclofenac capsules) | 8,679,544 |
| Cadence Pharms., Inc. v. Agila Specialties Private Ltd., Inc., 14-8000 (D.N.J.) | Dec. 23, 2014 | Hon. Renee Marie Bumb | Ofirmev® (acetaminophen for injection) | 6,028,222 6,992,218 |
| AstraZeneca AB v. Andrx Labs, 14-8030 (D.N.J.) | Dec. 24, 2014 | Hon. Joel A. Pisano | Nexium 24HR® (esomeprazole magnesium delayed-release capsules) | 6,369,085 7,411,070 |
| Otsuka Pharm. Co., Ltd. v. Apotex Corp., 14-8074 (D.N.J.) | Dec. 24, 2014 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 8,017,615 8,580,796 8,642,760 8,759,350 |
| Agila Specialties Inc. v. Cephalon, Inc., IPR2015-00503 (PTAB) | Dec. 24, 2014 | N/A | Treanda® (bendamustine hydrochloride for infusion) | 8,436,190 |
| Novartis Pharms. Corp. v. Ranbaxy Inc., 14-1526 (D. Del.) | Dec. 29, 2014 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate capsules) | 6,894,051 RE43,932 |
| Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc., 14-8079 (D.N.J.) | Dec. 29, 2014 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) | 5,847,170 |
| Sanofi-Aventis U.S. LLC v. BPI Labs, LLC, 14-8081 (D.N.J.) | Dec. 29, 2014 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) | 5,847,170 |
| Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, 14-8082 (D.N.J.) | Dec. 29, 2014 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) | 5,847,170 |
| Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, 14-1533 (D. Del.) | Dec. 30, 2014 | Hon. Leonard P. Stark | Jevtana® Kit (cabazitaxel injection) | 5,847,170 7,241,907 |
| Sanofi-Aventis U.S. LLC v. BPI Labs, LLC, 14-3233 (M.D. Fla.) | Dec. 30, 2014 | Hon. Elizabeth A. Kovachevich | Jevtana® Kit (cabazitaxel injection) | 5,847,170 |
| Reckitt Benckiser Pharms. Inc. v. Par Pharma., Inc., 14-1573 (D. Del.) | Dec. 31, 2014 | Hon. Richard G. Andrews | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) | 8,900,497 8,906,277 |
| Reckitt Benckiser Pharms. Inc. v. Watson Labs., Inc., 14-1574 (D. Del.) | Dec. 31, 2014 | Hon. Richard G. Andrews | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) | 8,900,497 8,906,277 |
| Apotex, Inc. v. Novartis AG, IPR2015-00518 (PTAB) | Dec. 31, 2014 | N/A | Gilenya® (fingolimod capsules) | 8,324,283 |
